Diabetes care 2021 jan 44, Search Results
Tartalom
Drugs used to treat rheumatic and musculospastic disease.
In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. Philadelphia: Lippincott,pp.
User Login
Expert review of hepatotoxicity published inlong before the availability of sarilumab and other monoclonal antibodies.
Immunosuppressants, tolerogens, and immunostimulants.
- Cited By This article is cited by 45 publications.
- Lilly diabetes monitor diary
- A diabétesz 1 őssejtek
New York: McGraw-Hill,pp. Textbook of pharmacology and therapeutics.
- Wake Forest Baptist Medical Center Summary: Bradycardia -- a slower than normal heartbeat -- does not increase the risk of developing cardiovascular disease, according to a study.
- Это не был тот страх перед непосредственной угрозой для его я, который навалился на него там, в пещере самодвижущихся дорог.
- Ops decoction kezelés diabetes
- Az impotencia a diabetes mellitus okok és a kezelés
- Stacks Health Portal
Carroll MB. The impact of biologic response modifiers on hepatitis B virus infection. Expert Opin Biol Ther.
Bannwarth B, Richez C. Clinical safety of tocilizumab in rheumatoid arthritis. Expert Opin Drug Saf. Case of severe liver damage after the induction of tocilizumab therapy for rheumatoid vasculitis. Hepatol Res. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis ADACTA : a randomised, double-blind, controlled phase 4 trial.
Severe hepatitis associated with tocilizumab in a patient with rheumatoid arthritis. Rheumatology Oxford.
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].
Tocilizumab-induced acute liver injury in adult onset Still's disease. Case Reports Hepatol.
Ann Rheum Dis. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of diabetes care 2021 jan 44 phase III study.
Arthritis Rheumatol.
Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis MONARCH : a randomised, double-blind, parallel-group phase III trial. Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients 2ith active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors.
Scott LJ. Sarilumab: First global approval.
FDA safety review of elevations in liver associated enzymes during sarilumab therapy.
